Company intelligence / Profile preview

Kanisa

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Kanisa Pharmaceuticals was a clinical-stage biopharmaceutical company primarily focused on the development and commercialization of oncology therapeutics. The company's lead development programs centered on proprietary liposomal formulations of established chemotherapy agents, designed to improve efficacy and reduce systemic toxicity. Its most notable asset was a heat-activated liposomal doxorubicin, which progressed into late-stage clinical trials for various solid tumors. Kanisa was acquired by Celsion Corporation in 2005 to consolidate their efforts in heat-sensitive drug delivery technologies.

Therapeutic areas: Oncology
Modalities: Small moleculeLiposomal formulation
Industry: Biotech

Partnerships

Duke University

Beyond the preview

Go deeper on Kanisa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kanisa.

Explore the full profile